Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vor Biopharma Inc. - Common Stock
(NQ:
VOR
)
8.330
+0.380 (+4.78%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
293,612
Open
8.315
Bid (Size)
8.200 (300)
Ask (Size)
8.500 (500)
Prev. Close
7.950
Today's Range
8.119 - 8.660
52wk Range
2.622 - 65.80
Shares Outstanding
66,956,800
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Vor Biopharma
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session.
↗
November 11, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Performance
YTD
-62.8%
-62.8%
1 Month
-67.3%
-67.3%
3 Month
-78.9%
-78.9%
6 Month
+108.4%
+108.4%
1 Year
-49.9%
-49.9%
More News
Read More
Let's take a look at the stocks that are in motion in today's session.
↗
November 11, 2025
Via
Chartmill
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
↗
November 11, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 11, 2025
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 11, 2025
Via
Chartmill
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
↗
November 11, 2025
Via
Benzinga
US Stocks Mixed; Sea Shares Gain After Q3 Results
↗
November 11, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
↗
November 11, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 11, 2025
Via
Benzinga
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
↗
November 11, 2025
Via
Benzinga
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025
From
Vor Biopharma
Via
GlobeNewswire
These stocks are moving in today's after hours session
↗
November 10, 2025
Via
Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 10, 2025
Via
Benzinga
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
November 10, 2025
From
Vor Biopharma
Via
GlobeNewswire
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
November 03, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
From
Vor Biopharma
Via
GlobeNewswire
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
October 29, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
October 22, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
October 17, 2025
From
Vor Biopharma
Via
GlobeNewswire
Novartis Strengthens Kidney Disease Pipeline With Promising Data
↗
October 16, 2025
Via
Benzinga
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
October 16, 2025
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears
↗
October 14, 2025
Via
Benzinga
Frequently Asked Questions
Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 8.330
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 11/28/25 01:00 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 557.75M
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 558M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.